Stämm is developing compact, continuous biomanufacturing systems for biologics and cell therapies.

Its mission is to make bioprocesses easy, scalable, sustainable, and repeatable, inspired by nature's solutions, unleashing the full potential of biotechnology and freeing partners to focus on the disruptive discoveries that impact people's lives.

PROFILE

Sector: Biotechnology

Type of product: Biomanufacturing solutions

Foundation date: 2016
People in the team: 200



Yuyo Llamazares Vegh Co-founder & CEO

Lead inventor of the bioreactor technology & strong leader with expertise in disciplines including microbiology, synthetic biology, nanotechnology, and microfluidics.



Federico D'Alvia Vegh Co-founder & COO

10+ years of sales and market development and operations. He has successfully led five infrastructure expansions.



Juan Martín Cabaleiro, PhD. CTO

10+ years of scientific research in fluid dynamics, laser graving, 3D printing, and microfabrication.



Manuel del Cogliano, PhD. CSO

Microbiology, cellular, and molecular biology specialist.



Verona Llamazares Vegh CFO

12+ years of managing accounting, purchases, and budget, for national a branch of Shell.



Román Ortega Bianchi Head of BD

MBA with 10+ years experience in business development, sales & marketing strategy in the pharma industry in different countries.



Ignacio Campanelli Head of Product

Industrial designer. Co-inventor of Stämm's 3D printing technology and rendering software.



Martín Palazzo Head of Silico

7+ years of research in AI applications for biology and +10 years in the tech industry

Our Milestones



Stämm's structures its products and services in three segments:



Stämm's core solution is a continuous, bubble-free Bioprocessor, a biomanufacturing platform with a novel 3D-printed bioreactor that enhances yields, reduces costs and minimizes footprint and energy consumption.

Stämm's approach enables a scalable, energy-efficient solution that provides an ideal cell growth environment.



BIO AI


Stämm is developing a transomics platform that leverages insilico methods through their Multi-omic Network Atlas ($MoNA^{TM}$) allowing it to map the biomolecular behaviour of cells with its experimental ambient conditions.

With MoNA, biotechnologists and molecular biologists will be able to reduce the uncertainty and risk during wet lab assay design, execution, and interpretation. Therefore, achieving high-precision biomolecular decision-making.

BIOENGINEERING

Stämm is developing state-of-the-art devices for Cell Line Development with automated cell engineering, clone outgrowth & screening for the production of biologics.

This is being done through a **Bioengineering Platform**, an engineering and sorting platform powered by a high-throughput automated system to streamline workflows, and a **Clone Selection Platform**, a specialized solution that automates clone selection and screening, monitoring the process to optimize clients' pipelines.



info@stamm.bio www.stamm.bio